Emergent BioSolutions Inc.
EBS
$5.63
-$0.25-4.25%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 965.40M | 1.04B | 1.13B | 1.10B | 1.19B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 965.40M | 1.04B | 1.13B | 1.10B | 1.19B |
| Cost of Revenue | 610.80M | 667.60M | 716.80M | 765.30M | 659.60M |
| Gross Profit | 354.60M | 376.00M | 408.70M | 336.90M | 525.80M |
| SG&A Expenses | 266.60M | 298.70M | 327.40M | 331.20M | 345.20M |
| Depreciation & Amortization | 65.20M | 65.10M | 65.00M | 65.00M | 64.80M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.01B | 1.10B | 1.22B | 1.27B | 1.18B |
| Operating Income | -41.00M | -51.60M | -89.50M | -165.10M | 10.00M |
| Income Before Tax | -62.30M | -142.90M | -169.80M | -578.10M | -558.50M |
| Income Tax Expenses | 69.30M | 47.70M | 39.00M | 8.90M | 6.80M |
| Earnings from Continuing Operations | -131.60 | -190.60 | -208.80 | -587.00 | -565.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.60M | -190.60M | -208.80M | -587.00M | -565.30M |
| EBIT | -41.00M | -51.60M | -89.50M | -165.10M | 10.00M |
| EBITDA | 62.40M | 54.00M | 19.50M | -54.90M | 124.60M |
| EPS Basic | -2.55 | -3.63 | -4.00 | -11.25 | -11.02 |
| Normalized Basic EPS | -0.33 | -1.30 | -1.69 | -3.02 | -1.01 |
| EPS Diluted | -2.71 | -3.73 | -4.11 | -11.25 | -11.03 |
| Normalized Diluted EPS | -0.43 | -1.35 | -1.73 | -3.02 | -1.01 |
| Average Basic Shares Outstanding | 214.30M | 212.10M | 209.80M | 208.50M | 206.60M |
| Average Diluted Shares Outstanding | 219.70M | 214.60M | 212.30M | 208.50M | 206.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |